Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: A systematic review meta-analysis

Rheumatology (United Kingdom)

Volumn 56, Issue 3, 2017, Pages 417-425

  Tarp, Simon ^a   Furst, Daniel Eric ^b,c,d   Boers, Maarten ^e,f   Luta, George ^g   Bliddal, Henning ^a   Tarp, Ulrik ^h   Asmussen, Karsten Heller ^a   Brock, Birgitte ^h   Dossing, Anna ^a   Jørgensen, Tanja Schjødt ^a   Thirstrup, Steffen ⁱ   Christensen, Robin ^a  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FLORENCE   (Italy)

^e Department of Epidemiology and Biostatistics ^*  (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biological agents; Indirect comparison; Meta analysis; Mortality; Network metaanalysis; Rheumatoid arthritis; Serious adverse events; Systematic review; Targeted synthetic disease modifying antirheumatic drugs

Indexed keywords

ABATACEPT; ADALIMUMAB; ANAKINRA; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; TOFACITINIB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; BIOLOGICAL THERAPY; COCHRANE LIBRARY; COMPARATIVE EFFECTIVENESS; DRUG APPROVAL; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; EMBASE; GRADING OF RECOMMENDATIONS ASSESSMENT DEVELOPMENT AND EVALUATION APPROACH; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; NETWORK META-ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REGISTER; RHEUMATOID ARTHRITIS; RISK; SIDE EFFECT ASSESSMENT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; POISSON DISTRIBUTION; REGRESSION ANALYSIS;

ABATACEPT; ADALIMUMAB; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CERTOLIZUMAB PEGOL; ETANERCEPT; HUMANS; NETWORK META-ANALYSIS; PIPERIDINES; POISSON DISTRIBUTION; PYRIMIDINES; PYRROLES; REGRESSION ANALYSIS; RISK; RITUXIMAB;

EID: 85021855305     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew442     Document Type: Article

References (43)

1. Smolen JS, Landewé, R Breedveld, FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
2. Singh JA, Saag KG, Bridges SL Jr et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016;68:1-20.
3. Singh JA, Christensen R, Wells GA et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;(4):CD007848.
4. Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials 2012;13:138.
5. Bradburn MJ, Deeks JJ, Berlin JA, Russell LA. Much ado about nothing: a comparison of the performance of metaanalytical methods with rare events. Stat Med 2007;26:53-77.
6. Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;(2):CD008794.
7. Desai RJ, Hansen RA, Rao JK et al. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis. Ann Pharmacother 2012;46:1491-505.
8. Moulis G, Sommet A, Bé né J et al. Cancer risk of anti- TNF-a at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One 2012;7:e48991.
9. Aaltonen KJ, Virkki LM, Malmivaara A et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012;7:e30275.
10. Alonso-Ruiz A, Pijoan JI, Ansuategui E et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52.
11. Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
12. Bongartz T, Warren FC, Mines D et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009;68:1177-83.
13. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006;33:2398-408.
14. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:898-908.
15. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68: 1136-45.
16. Baji P, Péntek M, Czirják L et al. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ 2014;15:S53-64.
17. Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med 2014;127:1208-32.
18. Food and Drug Administration. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics.2010. http://www.fda.gov/downloads/Drugs/Guidances/ ucm201790.pdf (8 April 2015, date last accessed).
19. Ruiz GV, Jobanputra P, Burls A et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2014;9:CD007649.
20. Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH Therapeutic Review: Clinical and Economic Overview: Biological Response Modifier Agents for Adults with Rheumatoid Arthritis. 2010. http://www. cadth.ca/media/pdf/TR_RA_Clinical_and_Economic_ Overview_e.pdf (28 March 2015, date last accessed).
21. Guyatt GH, Oxman AD, Kunz R et al. Incorporating considerations of resources use into grading recommendations. BMJ 2008;336:1170-3.
22. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 The Cochrane Collaboration. [Updated March 2011]. www.cochranehandbook. org (26 July 2013, date last accessed).
23. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151:W65-94.
24. Tarp S, Tarp U, Furst DE et al. Risk of serious adverse effects and death associated with biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: protocol for a systematic review and meta-analysis of randomized controlled trials. PROSPERO 2014:CRD42014014842. http://www.crd. york.ac.uk/PROSPERO/display_record.asp?ID=CRD 42014014842 (24 November 2016, date last accessed).
25. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
26. Ioannidis JP, Evans SJ, Gøtzsche PC et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141: 781-8.
27. Sherman RB, Woodcock J, Norden J, Grandinetti C, Temple RJ. New FDA regulation to improve safety reporting in clinical trials. N Engl J Med 2011; 365:3-5.
28. Higgins JP, Altman DG, Gøtzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
29. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011;64:380-2.
30. Puhan MA, Schünemann HJ, Murad MH et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630.
31. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 2002;21:1575-600.
32. Mills EJ, Ioannidis JP, Thorlund K et al. How to use an article reporting a multiple treatment comparison metaanalysis. JAMA 2012;308:1246-53.
33. Bykerk VP, Cush J, Winthrop K et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis 2015;74:96-103.
34. Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol 2002;2:3.
35. Singh JA, Cameron C, Noorbaloochi S et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015;386:258-65.
36. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. PLoS ONE 2012;7:e41174.
37. ICH Expert Working Group. ICH harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting E2A. October 1994. ICH. http://www.ich.org/fileadmin/Public_Web_Site/ICH_ Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline. pdf (24 November 2016, date last accessed).
38. Food and Drug Administration (FDA). What is a Serious Adverse Event? 2014. http://www.fda.gov/Safety/ MedWatch/HowToReport/ucm053087.htm (27 March 2015, date last accessed).
39. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011;8:e1001026.
40. Schünemann HJ, Tugwell P, Reeves BC et al. Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. Res Syn Meth 2013;4:49-62.
41. Ramiro S, Gaujoux-Viala C, Nam JL et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:529-35.
42. Ferriols-Lisart R, Ferriols-Lisart F. Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under realworld settings: a systematic review. Rheumatol Int 2015;35:1193-210.
43. Keystone E, Heijde D, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study. Arthritis Rheum 2008;58:3319-29.